摘要:
The present invention is based on the studies of the pathogenic role of CCL17-expressing DCs and their effector function in inflammatory diseases, particularly in atherosclerotic diseases. It relates to agents inhibiting the binding reaction between a CCL17 cytokine and a CCL17 receptor for use as a medicament ( Fig. 5a ).